Prostatype Genomics
Prostatype Genomics publishes Annual Report for 2024
Prostatype Genomics AB today publishes the Annual Report for the financial year of 2024. The translated Annual Report is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com
Please note that the English version is a translation of the Swedish original.
For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01
e-mail: fredrik.rickman@prostatypegenomics.com
About Prostatype Genomics AB
Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.
Certified Adviser
Carnegie Investment Bank AB (publ)
Telephone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se
| Datum | 2025-04-24, kl 17:10 |
| Källa | MFN |
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID